Document resource
Early in the 20th century, Osler published his famous Law of life: ‘…no two individuals react alike under the abnormal conditions which we know as disease’. Cystic fibrosis (CF) obeys this law, people sharing identical CFTR gene variants often differing in phenotype.1 CFTR modulators were the first drugs to restore CFTR protein function through stabilisation (correctors) and channel activity (potentiators). Combinations, both dual and more so triple, have demonstrated multi-organ benefits. 2 However, around mean improvements in pulmonary outcomes and sweat chloride (diagnostic hallmark/CFTR functional biomarker), interindividual variability is a poorly understood characteristic of most studies.